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Intraperitoneal (IP) vancomycin is widely used to treat Gram-positive peritonitis
associated with peritoneal dialysis. There have been two cases of red man syndrome
(RMS), a vancomycin-speciﬁc nonimmunologic reaction, associated with IP vanco-
mycin. However, immune-mediated hypersensitivity reaction to IP vancomycin has
not yet been reported. A 49 year old woman on continuous ambulatory peritoneal
dialysis developed her ﬁrst peritonitis episode. The patient was treated with IP
vancomycin once/wk for 4 weeks. She experienced mild itching and ﬂushing
throughout her body for 1 day after the second treatment. Whenever vancomycin
was administered, generalized urticaria and a prickling sensation developed, and the
intensity increased gradually; however, these symptoms improved after vancomycin
was discontinued. An allergic skin test was performed 6 weeks after the previous
urticarial episode, and an intradermal skin test revealed a positive response to
vancomycin. To our knowledge, this is the ﬁrst case report of immunoglobulin E-
mediated hypersensitivity reaction to IP vancomycin administration.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vancomycin is a commonly used tricyclic glycopeptide anti-
biotic for the broad range of Gram-positive bacteria. Increased
vancomycin use has frequently been demonstrated to produce
various adverse drug reactions. The most common toxicity
associated with vancomycin is red man syndrome (RMS). Other
adverse effects reported include anaphylaxis [1], vasculitis,
ototoxicity, ﬁxed drug eruptions, fever, phlebitis, nephrotoxicity,
interstitial nephritis, agranulocytosis, thrombocytopenia, linear
immunoglobulin (Ig)A bullous dermatosis, toxic epidermal15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
y, Department of Internal
ter, 170 Hyeonchung-ro,necrolysis, and more rarely Stevens–Johnson [2], or drug rash
with eosinophilia and systemic symptoms syndrome.
Intraperitoneal (IP) vancomycin is widely used to treat
Gram-positive peritonitis associated with peritoneal dialysis.
Vancomycin-related adverse reactions are usually associated
with intravenous administration or, less frequently, with oral
administration [3,4]. There have been few reports regarding
adverse reactions to vancomycin after IP administration, except
for two cases of RMS [5,6]. However, to our knowledge, this
report is the ﬁrst to describe a case of IgE-mediated hypersen-
sitivity reaction after IP administration of vancomycin.Case report
A 49 year old, 53 kg woman on continuous ambulatory
peritoneal dialysis since August 2011 developed her ﬁrsthrology. Published by Elsevier. This is an open access article under the
Figure 1. Pruritic diffuse erythematous patches on the thigh.
Kidney Res Clin Pract 34 (2015) 57–5958episode of peritonitis in February 2014. She had hypertension
and hypothyroidism, with no recent changes in medication.
She did not have any allergic disease or previous episodes of
hypersensitivity reaction.
The patient visited our hospital because she experienced
cloudy efﬂuent for 1 day. She did not have abdominal pain or
fever, and physical examination showed no abdominal tender-
ness. Turbid dialysis efﬂuent was observed, and white blood
cell (WBC) count of the efﬂuent was 2,300/mm3, of which 85%
was comprised of polymorphonuclear leukocytes (PMNL).
Empirical antibiotic therapy with IP tobramycin and cefazolin
was started at our outpatient clinic.
On her second visit the next week, efﬂuent culture revealed
Micrococcus luteus (Gram-positive aerobic cocci that are com-
monly found in the environment and can be opportunistic
pathogens in immunocompromised patients). Her antibiotic
regimen was changed to 2 g of IP vancomycin/wk. Two grams
of vancomycin was mixed with 2 L of 1.5% dialysate and
instilled into the peritoneal cavity within 15 minutes. Vanco-
mycin was administrated once/wk for 3 weeks during her ﬁrst
peritonitis episode.
A few hours after the second administration of vancomycin,
the patient experienced ﬂushing and pruritus throughout her
body, which lasted for a few days. Following the third admin-
istration, the patient experienced a prickling sensation, pruritus,
and a ﬂushing sensation approximately 20 minutes after com-
pletion of the instillation. A skin rash, which lasted for 1 week,
occurred in the cervicofacial area, extended over the trunk, and
into her upper extremities and upper leg area. WBC count of the
efﬂuent decreased to 50/mm3 with no PMNL after the ﬁrst
vancomycin administration, and a zero cell count was recorded
after the third administration, which is also when the follow-up
efﬂuent culture yielded no growth of any microorganism.
The patient developed a second episode of peritonitis 25
days after the last vancomycin administration. As with the
previous episode, she had turbid efﬂuent with no subjective
symptoms, and WBC count of the efﬂuent was 1,800/mm3
with 83% PMNL. We started IP vancomycin and tobramycin at
our outpatient clinic. Ten minutes after vancomycin adminis-
tration, she developed a severe prickling sensation, pruritus,
generalized urticarial rash, and throat tightness (Fig. 1). Intra-
muscular epinephrine with intravenous antihistamine and
dexamethasone were applied once because of the possibility
of anaphylaxis, and the patient was admitted. Her vital signs
were as follows: blood pressure, 130/80 mmHg; pulse rate,
95 beats/min; body temperature, 371C; and respiratory rate,
20 breaths/min. There was no wheezing during physical exam-
ination. Laboratory tests results were as follows: WBC, 6,500/
mm3; hemoglobin, 10.2 g/dL; platelet, 176,000/mm3; blood
urea nitrogen, 41.31 mg/dL; creatinine, 6.71 mg/dL; eosinophil
count, 480/mm3 (reference 50–500/mm3), and total IgE
3,240 IU/L (reference 0–100 IU/L). WBC count of the efﬂuent
was 50/mm3 with no PMNL.
Daily administration of IP tobramycin (40 mg) was main-
tained, and antihistamine with topical steroid cream was
applied. During her stay at the hospital, her symptoms
gradually improved and subsequent efﬂuent cell count
remained zero. She was discharged after 3 days with no skin
rash or pruritus. Efﬂuent culture yielded no growth at the time
of discharge, so the patient was discharged with IP cefazolin
with oral ciproﬂoxacin. Five days after she visited our hospital,
WBC count of the efﬂuent was 25/mm3 with no PMNL, and
culture obtained upon admission yielded Micrococcus luteus.Oral linezolid was prescribed because there was possible a
cross-reactivity with teicoplanin [7]. Six weeks after the
previous urticarial episode, we performed an allergic skin test
with vancomycin. A skin prick test yielded negative results.
Subsequently, intradermal skin tests with 1:100,000 and
1:10,000 dilutions were performed. Vancomycin began to
elicit a response at a dilution of 1:10,000 (5 m/mL), with a
wheal diameter of 5 mm10 mm. A negative control test
using saline showed no response.Discussion
Vancomycin can cause several types of hypersensitivity
reactions, such as the anaphylactoid reaction known as RMS,
IgE-mediated immediate hypersensitivity reaction, and, less
frequently, delayed hypersensitivity reactions. To date, the
most common toxicity with vancomycin is RMS, which is
caused by vancomycin-induced nonimmunologic degranula-
tion of mast cells and basophils, resulting in the release of
histamine, independent of preformed IgE or complement [8].
RMS typically presents with pruritus and erythematous rash
that affects the face, neck, and upper torso. In many patients,
RMS presents as mild, transient pruritus at the end of the
infusion that subsequently vanishes [8].
Vancomycin-induced IgE-mediated immediate hypersensitivity
reactions are rare but do occur, and re-administration of vanco-
mycin can cause bronchospasm or cardiovascular collapse in
affected patients [1]. In this case, the patient is presumed to have
type I IgE-mediated hypersensitivity reaction to vancomycin. Her
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symptoms, which suggests immune-mediated sensitization. The
distribution of skin lesions was generalized rather than conﬁned
to the upper torso, which persisted over several days. The patient
experienced throat tightness that may be associated with laryn-
geal edema caused by type I hypersensitivity reaction. More
importantly, the positive result in the intradermal skin test using
vancomycin reﬂects a strong possibility of IgE-mediated hyper-
sensitivity reaction in our patient. Skin tests with drugs help to
determine the cause and mechanism of drug hypersensitivity
reactions. In type I IgE-mediated allergic drug reactions, skin prick
and intradermal tests may provide rapid and supportive evidence
for diagnosis or exclusion of IgE-mediated reactions [9]. Unfortu-
nately, vancomycin-speciﬁc IgE or vancomycin-induced basophil
activation test were not performed in this case, because they were
not available in our hospital. It is our limitation that such tests
were not performed to demonstrate more evidence of IgE-
mediated mechanism in drug hypersensitivity.
Linezolid and teicoplanin are alternative drugs that can be
used if a patient experiences vancomycin-induced anaphylaxis.
IP daptomycin might also be an alternative for treating Gram-
positive peritonitis in vancomycin-intolerant patients [10].
However, allergic cross-reactivity between vancomycin and
teicoplanin has been reported [7]. In this case, linezolid was
used because of the patient’s susceptibility toM. luteus and the
possibility of cross-reactivity with teicoplanin. Vancomycin
desensitization is a possible strategy to safely induce drug
tolerance and limit the possibility of a type I hypersensitivity
reaction [11].
Drug hypersensitivity reactions can be developed via multiple
administration routes, but one via the IP route is extremely rare.
There was only one previous case report of a hypersensitivity
reaction to IP administration of a chemotherapeutic agent (carbo-
platin) [12], but there have been no previous reports regarding IP
administration of antibiotics. Various antibiotics are used intraper-
itoneally to treat dialysis-associated peritonitis, including vanco-
mycin. IP vancomycin has been known to be associated with
chemical peritonitis [13], eosinophilic peritonitis [14], and RMS
[5,6]; however, there have been no previous reports on immune-
mediated hypersensitivity reactions.
Systemic absorption of vancomycin is evident even after IP
administration, thus making it natural for hypersensitivity reac-
tions to occur. However, in contrast to the case with intravenous
administration, early elevations of vancomycin concentration in
serum are avoided when the drug is given intraperitoneally, and
overall absorption rate is slower. These high concentrations are
thought to elicit more frequent histamine-mediated reactions
during intravenous vancomycin therapy [15].
To our knowledge, this is the ﬁrst case of IgE-mediated
hypersensitivity reaction induced by IP vancomycin. Cliniciansshould keep in mind that hypersensitivity reactions may occur
even when vancomycin is administered intraperitoneally.Conﬂict of interest
The authors report no conﬂicts of interest.
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